AI Summary
✦ ClarthaValuation Metrics
Trading 22.1% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.63). Confidence: 84%.
Live forward EPS implies next-12-month EPS of ₹11.01. Applying the stock's normalized valuation corridor produces a fair range of ₹980.00 to ₹1,218.59, with base value near ₹1,126.65 (+164.5% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹11.01
Forward P/E
38.7x
Base Fair Value
₹1,126.65
Fair Range
₹980.00 - ₹1,218.59
Upside To Base
+164.5%
Estimate Source
Live forward EPS
Growth Estimate
+234.6%
5Y Average
94.70
Current
124.93
Overvalued
110.68
Undervalued
89.01
5Y Average
3.04
Current
4.00
Overvalued
3.49
Undervalued
2.58
5Y Average
17.59
Current
23.20
Overvalued
19.70
Undervalued
14.71
Peers & Comparison
Sector: Health Care · Theme: Biotechnology
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ANTHEM BIOSCIENCES LTD ANTHEMBiotechnology | -22.6% | 28.7% | 82.7x Fair | -4% vs avg | +19.9% |
SAI LIFE SCIENCES LIMITED SAILIFEBiotechnology | +11.7% | 16.1% | 85.4x Fair | -1% vs avg | +60.0% |
ACUTAAS CHEMICALS LIMITED ACUTAASBiotechnology | +59.1% | 26.4% | 91.4x Fair | +6% vs avg | +149.2% |
ONESOURCE SPECL PHARMA L ONESOURCEBiotechnology | +37.2% | -3.1% | — | — | -16.9% |
BIOCON LIMITED. trades at a premium (125.9x vs peer avg 86.5x), implying higher growth or quality expectations from the Biotechnology cohort. Peers include ANTHEM BIOSCIENCES LTD, SAI LIFE SCIENCES LIMITED, ACUTAAS CHEMICALS LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹624 CrJun 2026Latest net profit
₹52 CrJun 2026Latest EPS
₹0.32Jun 2026Net margin
10.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 513 | 519 | 563 | 533 | 511 | 525 | 563 | 644 | 537 | 583 | 621 | 605 | 624 |
| Expenses + | 441 | 452 | 492 | 480 | 466 | 488 | 532 | 582 | 516 | 530 | 548 | 525 | 564 |
| Operating Profit | 72 | 67 | 71 | 52 | 45 | 38 | 31 | 62 | 21 | 53 | 73 | 79 | 61 |
| OPM % | 14% | 13% | 13% | 10% | 9% | 7% | 6% | 10% | 3.8% | 9% | 12% | 13% | 10% |
| Other Income + | 56 | 64 | 48 | 39 | 42 | 74 | 672 | 63 | 61 | 134 | -122 | 31 | 65 |
| Interest | 48 | 55 | 56 | 40 | 55 | 60 | 65 | 57 | 56 | 67 | 2 | 17 | 17 |
| Depreciation | 30 | 31 | 31 | 30 | 30 | 30 | 34 | 33 | 33 | 34 | 34 | 36 | 38 |
| Profit before tax | 50 | 46 | 33 | 22 | 1 | 21 | 604 | 35 | -8 | 86 | -84 | 57 | 70 |
| Tax % | 6% | 25% | 27% | 36% | 18% | 85% | 3% | 39% | 9% | 17% | -10% | 11% | 25% |
| Net Profit + | 47 | 35 | 24 | 14 | 1 | 3 | 584 | 21 | -8 | 71 | -76 | 51 | 52 |
| EPS in Rs | 0.39 | 0.29 | 0.20 | 0.12 | 0.01 | 0.03 | 4.86 | 0.18 | -0.06 | 0.53 | -0.57 | 0.31 | 0.32 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation